Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development

• Published in: Vaccine Vol. 31; no. 1; pp. 58 - 83
• Main Authors: Kushnir, Natasha, Streatfield, Stephen J, Yusibov, Vidadi
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 17-12-2012; Elsevier; Elsevier Limited
• Subjects: Allergy and Immunology; Aluminum; Animal models; Applied microbiology; Avian flu; Bacteria; Biological and medical sciences; Biotechnology; Clinical development; Cytotoxicity; Deoxyribonucleic acid; Development; DNA; E coli; Expression vectors; Fundamental and applied biological sciences. Psychology; fungi; Genetic engineering; Hepatitis; Heterologous expression system; HIV; Human immunodeficiency virus; Human papillomavirus; Humans; immune response; Immunogenicity; Lipids; Microbiology; Molecular weight; Pathogens; production technology; Proteins; recombinant antigens; recombinant proteins; Review; Structural proteins; Subunit vaccine; subunit vaccines; Tropical diseases; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, Virus-Like Particle - immunology; Viral Vaccines - immunology; Virosome; Virosomes - immunology; Virus-like particle; Virus-like particles; Viruses; Yeast; Heterologous expression system; Virosome; Virus-like particle; Subunit vaccine; Clinical development; Heterologous system; Virus like particle; Vaccine; Subunit
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2012.10.083

Highlights ► Virus-like particles (VLPs) are a class of recombinant subunit vaccines. ► VLPs resemble native viruses but lack infectious genetic material. ► VLPs are promising vaccines due to strong immunogenicity and safety. ► VLPs can be produced in prokaryotic or eukaryotic expression systems, or in vitro . ► VLP-based vaccine candidates targeting many diseases are in clinical development.